<DOC>
	<DOCNO>NCT03069248</DOCNO>
	<brief_summary>This non-comparative , prospective , non-randomized single centre phase II clinical trial Rituximab alpha interferon immunotherapy follow autologous stem cell transplant patient relapse follicular lymphoma conduct Toronto Sunnybrook Regional Cancer Centre/Sunnybrook Women 's Health Sciences Centre .</brief_summary>
	<brief_title>Treatment Follicular Lymphoma With High Dose Therapy Stem Cell Support Followed Rituximab Alpha Interferon</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients 12 relapse WHO Classification follicle centre NHL grade 12/3 . Patients must achieve least PR previous treatment . Central pathology review registration Ann Arbor stage III IV Measurable disease : define clinically radiologically documented disease least one site bidimensionally measurable use clinical exam , CT MRI perform 3 week prior study enrollment . ECOG performance status &lt; 2 . Patients may receive 1 prior course ( 4 infusion ) rituximab . Timing rituximab must exceed 12 month prior registration . Patients must demonstrate least PR rituximab previously administer . Patient consent accord institutional university human experimentation committee requirement Adequate Renal , hepatic hematopoietic function test unless abnormal value think due involvement lymphoma define : Hb &gt; 85 ANC &gt; 1000/mm3 Platelets &gt; 100,000/mm3 Serum/Total Bilirubin &gt; =2 SI unit AST/ALT &lt; 2x Upper Limit Normal Positive serology HIV Uncontrolled Infection Pregnancy CNS Metastases History Psychiatric Disorder Other Malignancy ( except nonmelanoma skin cancer ) Serious nonmalignant disease ( e.g. , congestive heart failure , active uncontrolled bacterial , viral , fungal infection ) , condition , , opinion investigator and/or sponsor , would compromise protocol objective . Major surgery , diagnostic surgery , within four week . Presence antimurine antibody ( HAMA ) reactivity . These laboratory result must available prior receive treatment patient receive prior murine proteins patient allergy murine protein . New York Heart Association Class III IV heart disease ( see Appendix H , Clinical Evaluation Functional Capacity Patients Heart Disease Relation Ordinary Physical Activity ) myocardial infarction within past six month . Treatment investigational drug within 30 day five halflives ( study drug long halflife ) prior entry study , ever long . Previous chemotherapy , immunotherapy , radiotherapy , investigational therapy treatment malignancy except basal cell squamous cell skin cancer carcinoma situ cervix within last 5 year . History allergic reaction compound chemically related Rituximab . Refusal practice contraception reproductive potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>